Fragrance Creators Association Amplifies Ongoing Collaboration and Shared Commitment With the FDA to Advance State-of-the-Art Science
October 17, 2022 13:30 ET
|
Fragrance Creators Association
WASHINGTON, Oct. 17, 2022 (GLOBE NEWSWIRE) -- The Director of the Food and Drug Administration's (FDA) Office of Cosmetics and Colors Linda Katz, MD, MPH, told members of the Fragrance Creators...
GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages Medtronic plc Investors to Secure Counsel Before Important Deadline in Securities Class Action – MDT
September 14, 2022 14:17 ET
|
The Rosen Law Firm PA
NEW YORK, Sept. 14, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the stock of...
ROSEN, A TOP RANKED LAW FIRM, Encourages Kiromic BioPharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – KRBP
August 16, 2022 14:53 ET
|
The Rosen Law Firm PA
NEW YORK, Aug. 16, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of...
Electrocardiograph (ECG) Market Size is projected to reach USD 10.79 Billion by 2030, growing at a CAGR of 5.67%: Straits Research
August 09, 2022 08:20 ET
|
Straits Research
New York, United States, Aug. 09, 2022 (GLOBE NEWSWIRE) -- North America is dominating the global electrocardiograph (ECG) market. In this regard, the United States has the largest market share. An...
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Spero Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – SPRO
June 05, 2022 17:15 ET
|
The Rosen Law Firm PA
NEW YORK, June 05, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Spero...
Neuronascent Receives FDA Orphan Drug Designation for NNI-351 Treatment of Fragile X Syndrome
June 01, 2022 06:00 ET
|
Neuronascent, Inc.
ROCKVILLE, Md., June 01, 2022 (GLOBE NEWSWIRE) -- Neuronascent Inc, today announced that the U.S. Food and Drug Administration (FDA) granted “Orphan Drug Designation” for the company’s NNI-351...
FDA Acknowledges Ligand Innovation Global’s Application for Emergency Use Authorization of LifeAir/VitaCaeli
March 03, 2022 09:00 ET
|
Forwardly, Inc.
Henderson, NV, March 03, 2022 (GLOBE NEWSWIRE) -- Forwardly, Inc. (OTCMKT: FORW) announced today that its partially owned subsidiary and partner, Ligand Innovation Global (“Ligand”), has received...
OWLT LOSS ALERT: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Owlet, Inc. Investors with Losses to Secure Counsel Before Important January 18 Deadline in Securities Class Action – OWLT
December 28, 2021 18:15 ET
|
The Rosen Law Firm PA
NEW YORK, Dec. 28, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds: (a) purchasers of the securities of Owlet, Inc. (NYSE: OWLT) between March 31, 2021 and...
OWLT NOTICE: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Owlet, Inc. Investors to Inquire About Class Action Investigation – OWLT
October 19, 2021 17:19 ET
|
The Rosen Law Firm PA
NEW YORK, Oct. 19, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Owlet, Inc....
Processa Pharmaceuticals Cleared by FDA to Proceed with Phase 2a Trial for the Treatment of Gastroparesis
October 12, 2021 08:30 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve...